ArriVent BioPharma reported that its phase 3 Furvent trial of firmonertinib in previously untreated patients with non-squamous locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival (PFS).
The study enrolled 398 patients who received either one of two doses of firmonertinib or platinum-based chemotherapy as first-line treatment. Firmonertinib is a brain-penetrant inhibitor designed to target both classical and uncommon EGFR mutations.
The trial had the potential to position firmonertinib as a chemotherapy-free treatment option for patients with EGFR exon 20 insertion-mutated NSCLC. However, the primary endpoint was not achieved based on blinded independent central review (BICR).
Progression-Free Survival Findings
Under the BICR analysis, patients who received the higher dose of firmonertinib achieved a median PFS of 11 months, compared with 9.5 months in the chemotherapy control arm. The lower dose of firmonertinib resulted in a median PFS of 8.4 months.
ArriVent also reported results based on investigator assessment. In that analysis, median PFS was 11.1 months for the higher-dose firmonertinib group and 7.1 months for patients in the control arm.
The company acknowledged that the outcome fell short of expectations. Chief Executive Officer Bing Yao said, “These disappointing results are not what we hoped for, particularly for the patients … who urgently need more effective treatment options.”
Yao also stated that the improvement in progression-free survival was not considered meaningful.
Response Rate and Survival Data
Although the study missed its primary endpoint, response rate results favored the higher dose of firmonertinib.
According to the BICR analysis, the objective response rate was 60% among patients receiving the higher dose of firmonertinib, compared with 33% in the control arm.
ArriVent said overall survival data remain immature. The company reported only a trend toward improvement in overall survival and did not provide mature survival results.
Safety Profile and Next Steps
The company reported that no new safety signals were identified during the trial. ArriVent said the safety profile observed in Furvent was consistent with earlier studies of firmonertinib.
Bing Yao said the company is evaluating the full dataset to determine the most appropriate development path for firmonertinib.
Beyond the Furvent study, firmonertinib is also being evaluated in a phase 3 trial involving NSCLC patients whose tumors contain uncommon EGFR PACC mutations. The therapy is approved in China for NSCLC patients with certain mutations.
Control Arm Performance and Market Reaction
Analysts noted that the chemotherapy control arm performed better than expected. BTIG analyst Jeet Mukherjee said the control group achieved 9.5 months of progression-free survival compared with expectations of roughly 7.5 to 8 months, while firmonertinib’s 11-month result was in line with expectations.
Following the release of the results, ArriVent shares opened down 57% at $12.37 in early trading. The decline came after the Phase 3 study failed to meet its primary endpoint.
Firmonertinib Phase 3 Study Misses Primary Endpoint
ArriVent BioPharma announced on October 6, 2026, that its Phase 3 FURVENT clinical trial of Firmonertinib did not meet its primary endpoint in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. The study evaluated whether Firmonertinib could improve progression-free survival compared with platinum-based chemotherapy plus pemetrexed.
Progression-free survival (PFS) measures how long patients live without their disease worsening or death occurring. Objective response rate, by contrast, measures the proportion of patients whose tumors shrink by a predefined amount following treatment.
These endpoints provide different insights into a cancer therapy’s performance. A treatment may produce tumor shrinkage in a substantial proportion of patients without delivering a statistically significant improvement in progression-free survival. This distinction is particularly important when evaluating targeted therapies for molecularly defined cancers.
In the FURVENT study, the differences between the response rates and PFS findings highlight why researchers must examine multiple clinical outcomes before determining a treatment’s overall value. The primary endpoint remains central to interpreting whether the trial achieved its main objective.
Why EGFR Exon 20 Insertion Mutations Are Difficult to Treat
EGFR exon 20 insertion mutations are genetic alterations that can drive the growth of certain lung cancers. These mutations differ from more common EGFR alterations, and their structural characteristics have historically made them challenging targets for some conventional EGFR inhibitors.
